Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis
|
|
- Claud Allen
- 5 years ago
- Views:
Transcription
1 Journal of Crohn s and Colitis (2007) 1, available at Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis N. Eleftheriadis a,, G. Lambrecht b,g.d Haens c, F. Baert d, M. Cabooter e, E. Louis f, G. Van Assche g, P. Schurmans h, P. Caenepeel i, M. Van Outryve j, P. Lammens k, A. Van Gossum l,m.devos a on behalf of the Belgian IBD Research Group a Department of Gastroenterology, Ghent University Hospital (UZ Gent), De Pintelaan Gent, Belgium b AZ Damiaan, Oostende, Belgium c Imelda Hospital Bonheiden, Belgium d Heilig Hart Ziekenhuis, Roeselaere, Belgium e A.Z.Sint-Jan AV, Brugge, Belgium f University Hospital of Liege, Belgium g University of Leuven, Belgium Gert h CAZ Hasselt, Belgium i ZOL Campus St. Jan, Genk, Belgium j Universitair Ziekenhuis Antwerpen, Edegem, Belgium k St. Jean Brussel, Belgium l Erasme Hospital, Brussels, Belgium Received 7 May 2007; accepted 1 June 2007 KEYWORDS Ulcerative colitis; Mesalamine; Corticosteroids; Immunosuppressives; Maintaining remission therapy; Extension of colitis Abstract Background and aim: Although the efficacy of maintenance remission therapy in ulcerative colitis (UC) has been proved in many studies, little is known about its possible effect on the extent of the disease. The aim of the present multicenter Belgian study was to evaluate the potential role of UC maintenance therapy on the colonic extension of the disease. Materials and methods: A total of 98 patients, 56 males, 42 females, mean age 52 years, range years, from 12 medical centers in Belgium, with an acute exacerbation of wellestablished, endoscopically and histologically proven left-sided UC, were included. The colonic extension was endoscopically determined at the time of the initial diagnosis and at the actual Corresponding author. Perdika 13, Ptolemaida, PC 50200, Greece. Tel.: ; fax: On behalf of Prof. Dr. Martine DeVos, Gastroenterology Department, University Hospital Ghent (UZ Gent), De Pintelaan , Gent, Belgium. Tel.: ; fax: addresses: nikoseleftheriadis@yahoo.com, eleftnik@otenet.gr (N. Eleftheriadis), glambrecht@azdamiaan.be (G. Lambrecht), geert.dhaens@imelda.be, geert.dhaens@uz.kuleuven.ac.be (G. D Haens), FBaert@hhr.be (F. Baert), gastrologie@azbrugge.be (M. Cabooter), edouard.louis@ulg.ac.be (E. Louis), Gert.VanAssche@uz.kuleuven.ac.be (G.V. Assche), gaen@clstjean.be (P. Lammens), andre.van.gossum@ulb.ac.be (A.V. Gossum), Martine.DeVos@UGent.be (M. De Vos) /$ - see front matter 2007 European Crohn s and Colitis Organisation. Published by Elsevier B.V. All rights reserved. doi: /j.crohns
2 22 N. Eleftheriadis et al.. The mean duration of UC was months, median was 84 months, and range was months. Active smoking was reported in only 7% of patients, while the majority were nosmokers (63%) or ex-smokers (30%). The median colonic extension at the time of initial diagnosis was 25 cm, range 2 70 cm from the anal merge. Sixty-six percent of the patients had quiescent disease without s during last year. The χ 2 -test was used for statistical analysis. Results: 29/98 (29.6%) patients had not used any maintenance therapy in the last 3 months before the actual exacerbation. The most commonly used maintenance therapy was 5-ASA (43%), while combined therapy with 5-ASA, corticosteroids or immunosuppresives (mainly azathioprine) in all possible combinations was reported by 29.6% of patients. The extent of UC had not changed in 50.7% and 51.7% of patients, respectively, with and without maintaining therapy (NS, p=0.99). Some degree of regression was observed in, respectively, 21.7% and 20.7% (NS, p= 0.99), and some degree of extension in, respectively, 27.5% and 27.6% (NS, p= 0.99). Furthermore, no relationship was found between changes in colonic extent and type of maintaining therapy, smoking habits or disease activity during the last year before the acute exacerbation. A tendency of beneficial effect of maintenance therapy on disease extent was observed in patients with continuous active disease of short duration. Conclusions: According to this multicenter study, maintenance remission therapy for left-sided UC was not found to have a statistically significant effect on colonic extension. Further longterm studies are necessary to confirm these results European Crohn s and Colitis Organisation. Published by Elsevier B.V. All rights reserved. 1. Introduction Despite the progress that has been made in the management of ulcerative colitis (UC) in the last decades, its natural history is still characterized by periods of remission interspersed with exacerbations, while the therapy is aimed to keep the general condition of the patient stable, maintaining remission whenever possible. 1 3 The efficacy of long-term maintenance therapy for ulcerative colitis with aminosalicylates has been well established in many studies. Mesalazine is the drug of choice for maintaining remission in patients with ulcerative colitis. 4 7 For more serious cases maintenance therapy with immunosuppressives, such as azathioprine, has been proven effective in patients with steroid-dependent or steroid-resistant ulcerative colitis However, little is known about the potential efficacy of maintenance therapy in modifying or changing the natural history of ulcerative colitis and the extent of the chronic inflammation. The aim of the present multicenter study was to evaluate the role of long-term maintaining therapy for ulcerative colitis on the colonic extension during subsequent exacerbations. 2. Patients and Methods In the present multicenter, cross-sectional study from 12 medical centers in Belgium, patients with actual exacerbation of well established, endoscopically and histologically proven left-sided UC were included. The same clinical questionnaire was used for all patients and included date of birth, sex, disease duration, smoking habits and date of initial diagnosis and actual and previous s. The extension of UC was endoscopically determined at the time of the initial diagnosis and at the actual flare up. Colonic extension was classified in two groups: Left-sided colitis including (a) rectum, (b) sigmoid and (c) descending colon, and pancolitis including (d) colitis up to the transversum and (e) pancolitis. Disease was determined as inactive if no flare up was recorded in previous year. Furthermore, a detailed history and chart review were retrospectively taken from all patients regarding their initial management and intake of maintenance therapy at the time of actual, as well as during 3 and 6 months before the actual UC exacerbation. According to UC maintenance remission therapy, all patients were classified in seven groups: (1) no therapy; (2) 5-aminosalicylate (5- ASA) only; (3) corticosteroids only; (4) immunosuppressive only; (5) 5-ASA and corticosteroids; (6) corticosteroids and immunosuppressives and (7) 5-ASA, corticosteroids and immunosuppressives. Finally, the change in colonic involvement (regression or extension) between the actual UC exacerbation and the initial localization was defined as: (a) minimal if the Table 1 Demographic and disease characteristics Baseline characteristics Left-side colitis (n= 98) Sex n (%) Male 56 (57%) Female 42 (43%) Age Median (range) 47 years (22 82) Smoking Non-smoker 63% Active smoker 7% Ex-smoker 30% Disease activity No in the previous year 66.3% One or more in the 33.7% previous year Duration of ulcerative colitis (UC) Mean +SD months Median (range) 84 months (3 372)
3 Maintaning therapy and extension of UC 23 Figure 1 Initial UC localization in relation to maintenance remission therapy. Table 3 Changes in UC extension in relation to maintenance remission therapy the last 3 months before the actual Change in UC extension No change Regression Extension Total population (n=98) 50 (51%) 21 (21.4%) 27 (27.6%) With maintenance therapy (n=69) 35 (50.7%) 15 (21.7%) 19 (27.5%) Without maintenance therapy (n=29) 15 (51.7%) 6 (20.7%) 8 (27.6%) pb0.005 (extension or regression vs. no change in total population). change in colonic extension involved one colonic segment according to the above-mentioned five-scale classification; (b) moderate (regression or extension) if involving two colonic segments; (c) important if involving three colonic segments and (d) very important if involving four colonic segments Statistics Continuous data are reported as mean±sd or median and ranges if the data were not normally distributed. For comparison of categorical data the χ 2 -test was used. All calculations were performed with SPSS version 10.1 software (SPSS, Chicago, IL). 3. Results Finally, a total of 98 randomly recruited patients, 56 males and 42 females, with mean age of 52 years and age range of years, with actual exacerbation of well established, endoscopically and histologically proven left-sided UC were included. The baseline demographic and disease history characteristics of all patients are reported in Table 1. The median time interval between initial diagnosis and actual flare up was 84 months (range months). At the time of initial diagnosis, the majority of patients with left-sided colitis had rectosigmoid disease (78%), while a minority had colitis up to the descending colon (22%). Mean colonic extension was cm, range 2 70 cm from the anal merge. The initial UC localization, with and without maintenance therapy during the last three months before the actual exacerbation, is shown in Fig. 1. Maintenance therapy, during the period of 3 and 6 months before the actual exacerbation, was taken by, respectively, 70% and 74% of patients (Table 2). Monotherapy with 5-ASA was the commonest therapy used by 43% of patients as monotherapy and in 21% of patients in combination with corticosteroids (12%), immunosuppressives (3%) or both (6%). Corticosteroids or immunosuppressives during the 6 months before the actual exacerbation alone or in combination with other drugs were used in, respectively, 22% and 14% of patients. Topical therapy with 5-ASA alone or in combination with corticosteroids was reported by 19% of patients, oral therapy by 29% and combined oral and local therapy by 22%, 3 months before the actual. In the total population no changes in colonic extension between the actual flare up and the initial localization were found in 51% of patients, while significantly less patients experienced some form of extension (27.6% of patients; p = ) or regression (21.4%; p = ) irrespective of use of maintenance therapy (Table 3). In 69 patients on maintenance therapy, the extent remained unchanged in 50.7%, regressed in 21.7% and extended in 27.5% of patients. Table 2 Medical treatment of left-sided UC at the time of initial diagnosis, actual, as well as during 3 and 6 months before the actual exacerbation Therapy Initial diagnosis Actual 3 months before actual 6 months before actual % (cumulative) % (cumulative) % (cumulative) % (cumulative) 5-ASA only 62% (62%) 43% (43%) 43% (43%) 47% (47%) Corticosteroids only 6% (68%) 3% (46%) 2% (45%) 2% (49%) Immunosuppressive only 0% (68%) 3% (49%) 2% (47%) 3% (52%) 5-ASA and corticosteroids 28% (96%) 11% (60%) 12% (59%) 11% (63%) 5-ASA and immunosuppressive 0% (96%) 2% (62%) 3% (62%) 2% (65%) Corticosteroids and immunosuppressive 1% (97%) 3% (65%) 2% (64%) 1% (66%) 5-ASA and corticosteroids and immunosuppressive 1% (98%) 4% (69%) 6% (70%) 8% (74%) No 2% (100%) 31% (100%) 30% (100%) 26% (100%)
4 24 N. Eleftheriadis et al. Table 4 Initial UC localization Change in UC extension in relation to initial colonic localization Change in UC extension No change Regression Extension Rectum % 37.1% 100.0% Sigmoid % 22.0% 26.8% 100.0% Descendens % 54.6% 13.6% 100% Total % 21.4% 27.6% 100.0% pb0.05 (extension vs. regression). Total Percentages were similar in patients without any form of maintenance treatment during the last 3 months (Table 3). In patients with initial colonic localization up to the descendens, significantly greater degree of regression (55%) than extension (14%) (p b 0.05) was observed, while patients with initial rectal disease showed either no change (63%) or extension (37%) of colonic extent. Half of the patients (51%) with initial sigmoidal disease showed no change in extent of colitis, while, respectively, 22% showed regression and 27% extension of colitis, irrespective to maintenance therapy (Table 4). The degree of regression was always mild to moderate in all patients with reduction in colonic extent, while extension of disease was mild to moderate in 20/27 (74%) patients and large to very large in 7/27 (26%), irrespective to maintenance therapy. In all groups, 66 to 77% of patients were on maintenance therapy. Type of maintenance therapy (local or oral) had also no influence on extension of disease (Table 5), while no beneficial effect on the extent of colonic disease was observed by the use of combined drug categories (Fig. 2). In the total population we found no correlation between changes in colonic extension and disease activity: no changes were found in 54% and 45% of patients with quiescent vs. active disease, regression of colonic extension in, respectively, 18% and 27% and progression in 28% and 27%. However, in the subgroup without maintenance therapy a trend to greater regression was observed in patients with quiescent Table 5 Change in colonic extension in relation to the type of maintenance remission UC maintenance therapy the last 3 months before the actual Change in UC extension N (%) No Regression Extension change Without therapy 15 (52 %) 6 (21%) 8 (28%) 29 Oral only therapy 12 (43%) 7 (25%) 9 (32%) 28 Local only 11 (58%) 3 (16%) 5 (26%) 19 therapy Oral and local 12 (55%) 5 (23%) 5 (23%) 22 therapy Total 50 (51%) 21 (21%) 27 (28%) 98 pn0.5 NS, in all groups studied. Total than with active disease. A tendency to opposite relationship was found in patients with therapy (15% vs. 31%, p=0.5) (Table 6). Active smoking was reported in only 7% of patients, while the majority of patients were no-smokers (63%) or exsmokers (30%). The relation between smoking habit and change in UC extension is shown in Table 7. A tendency to regression was observed in active smokers (45%) vs. nosmokers or ex-smokers (19%), although differences were not significant (p N 0.5). Finally, the relationship between mean UC duration in months and changes in colonic extension is presented in Fig. 3. The duration of the UC was more than 1 year in the majority of patients (92%). In patients with shorter disease duration (less than 1 year) either no change (63%) or regression (38%) of colonic involvement was observed, while in patients with more than 1 year disease duration, no change was observed in 50%, regression in 20% and extension in 30% of patients. 4. Discussion Ulcerative colitis is a chronic relapsing disease with frequent remissions and exacerbations. This intermittent course of UC represents the most significant inherent characteristic of its natural history. 1,2 Up to 90% of patients with UC have been reported to experience a chronic intermittent course, while according to the available literature, relapses of UC are still unpredictable, despite the progress that has been done the last decades in its management. 11,12 The efficacy of chronic maintenance therapy, mainly with aminosalicylates, on clinical symptoms and endoscopic healing has been shown in many studies, with follow-up periods ranging between 6 and 12 months. 1 4 Particularly, long-term maintenance therapy with aminosalicylates was found to be superior to placebo in maintaining remission (71% vs. 24% with sulfasalazine and placebo). 4,13 17 Furthermore, although great progress has been made the last decades concerning the understanding of the pathogenesis, genetic and environmental factors as well as the management of acute s, little is known about a possible modification of the extent of UC with long-term maintenance therapy. Especially, the role, if any, of chronic maintaining remission therapy for UC on the extent of colonic disease is unknown. 11,12,18
5 Maintaning therapy and extension of UC 25 Figure 2 Change in UC extension in relation to number of drug categories used as maintenance therapy. In a population-based study from Copenhagen, it is reported that the extent of UC is a dynamic process with changes with time in approximately half of the patients. They reported 25% cumulative probability of extension of colitis within 5 years in patients with proctosigmoiditis at initial diagnosis and 9% to 20% progression in patients with substantial colitis after 10 years of disease duration. The cumulative probability for regression in the above-mentioned study was 45% for substantial colitis and 58% for pancolitis after five years (Langholz et al. 11 ). Furthermore, Moum et al. 13 reported 16 24% progression and 23 25% regression rates in extent of colitis in patients with initial rectosigmoidal or left-sided disease, during a 1-year follow-up period using colonoscopy. Similar figures are also reported in the present study. Table 6 Change in UC extension in relation to last year s disease activity and maintenance therapy Maintenance therapy at 3 months Without therapy Last year s disease activity No Active disease Total No change % 75% 52% Regression % 21% Extension % 25% 28% Total % 100% 100% With therapy No change % 41% 51% Regression % 31% 22% Extension % 28% 28% Total % 100% 100% pn0.5 NS, in all subgroups studied. However, in the above-mentioned studies, the changes in UC extension were not correlated to chronic maintenance remission therapy, while in the study by Langholz et al. 11 the extent of UC was determined using sigmoidoscopy and double-contrast barium enema in contrast to the present study, in which the extent of UC was accurately determined using colonoscopy. In the present multicenter study the extent of UC seemed not influenced by the intake of maintenance therapy. Half of the patients had no change in extent whereas the other half of patients showed either regression (21%) or extension (28%) irrespective of use of maintenance therapy. The observed degree of extension or regression of colonic involvement was almost always minimal and only in 1 5% of patients more pronounced. The results of this study were not influenced by the type of medication (drug category, oral vs. local administration) nor by combination of different drugs. In fact, a small although insignificant trend to progression of anatomic involvement of disease was observed by the use of combined drug categories possibly reflecting the more aggressive form of disease. The most commonly used maintenance therapy was 5-ASA (47% of patients), while only a small number of patients (3%) was on immunosuppressive only therapy, making the interpretation of the results more difficult. Use of aminosalicylates was accompanied with an extension of disease in 24% and regression in 26% of patients. Furthermore, if we take into account that the mean time between previous and actual UC exacerbations in the current Table 7 Change in UC extension Effect of smoking habit in UC extension pn0.5 in all subgroups studied. Smoking habit No- and ex-smokers Active No change 53% 36% Regression 19.0% 45.0% Extension 28.0% 18.0%
6 26 N. Eleftheriadis et al. activity, may lead to a conclusion of a potential positive effect of maintenance therapy on colonic extent in patients with active disease. However the small number of patients precludes definite conclusions. In conclusion, although in our study chronic maintenance remission therapy for ulcerative colitis was not found effective in reducing the colitis extension during subsequent ulcerative colitis exacerbation, further long-term studies, as well as use of new drug categories, 21 are necessary to determine the role of chronic maintenance remission therapy for ulcerative colitis in the natural history of disease. Figure 3 Change in UC extension in relation to disease duration (months). study was 29 months, while the mean duration of UC was 93 months, the common follow-up period of 6 months to 1 year used in the majority of prospective studies concerning the role of maintenance therapy in UC, is not sufficient and further studies with longer follow-up are necessary to determine the efficacy of chronic maintenance therapy in modifying the extent of UC. As far as smoking habit is concerned, the majority of patients in this study were non-smokers or ex-smokers. Patients with active smoking showed the greatest degree of regression in colonic extension in comparison to non-smokers or ex-smokers, irrespective to maintenance therapy, however, without statistically significant differences. This finding is another indirect argument for the potential protective effect of smoking in UC, which is in accordance to other studies. 19,20 An interesting finding of this study was that in patients with short disease duration (less than 1 year) either no change (63%) or regression (38%) of colonic involvement was observed, in contrast to previous studies reporting the highest extension rate of ulcerative colitis during the first year of disease. 11 Use of maintenance therapy was even associated with larger regression (60%). However, the small number of patients precludes definite conclusions. Moreover, the mean disease duration was greater in patients with extension of ulcerative colitis (115 months) than in patients who showed no change (87 months) or regression (79 months) of ulcerative colitis extent (Fig. 3). Although the small number of patients made definite conclusions difficult, we could assume that ulcerative colitis patients during the first year after initial diagnosis may benefit from chronic maintenance therapy with regard to colitis extent. Finally, in the total population, patients with continuously active disease during the last year before actual, tended to show more frequently regression in colonic extent (27%) than patients with quiescent disease (18%) (p = 0.8, NS), in contrast to other studies, which reported that the occurrence of continuous active disease was related to extension of colitis. 11,13 Moreover, patients with active disease showed a trend to greater regression rate with maintenance therapy than patients with quiescent disease, although not significant, while in the group of patients without maintenance therapy, greater regression was observed in patients with quiescent disease. This inverse correlation of regression rates with and without maintenance therapy, in relation to disease References 1. Robinson M. Optimizing therapy for inflammatory bowel disease. Am J Gastroenterol 1997;92:12S 7S. 2. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn s disease. J Clin Gastroenterol 1995;20: Ardizzone S, Porro GB. A practical guide to the management of distal ulcerative colitis. Drugs 1998;55: Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol 2002:42 7 [Suppl]. 5. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med 1996;124: Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995;40: Mulder CJ, Tytgat GN, Weterman IT, Dekker W, Blok P, Schrijver M, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988;95: Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 1902;16: Fraser AG, Morton D, McGovern D, Travis S, Jewel DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16: Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91: Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996;31: Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107: Moum B, Ekbom A, Vatn MH, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999;94: Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1: Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:
7 Maintaning therapy and extension of UC Rijk MC, van Lier HJ, van Tongeren JH. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. Am J Gastroenterol 1992;87: Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000;95: Sinclair TS, Brunt PW, Mowat NA. Nonspecific proctocolitis in northeastern Scotland: a community study. Gastroenterology 1983;85: Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12: Russel MG, Stockbrugger RW. Epidemiological developments and insights in chronic inflammatory bowel diseases. Ned Tijdschr Geneeskd 2001;145: Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002;88(Suppl 1):S39 49.
Review article: the long-term management of ulcerative colitis
Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 97 101. Review article: the long-term management of ulcerative colitis S. B. HANAUER Section of Gastroenterology, University of Chicago, Chicago, IL, USA SUMMARY
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationINTESTINAL DISEASE MEETING BERLIN Topical steroids rectal application
INTESTINAL DISEASE MEETING BERLIN 2006 Topical steroids rectal application Prof. Dr. med. T. Andus Department of Internal Medicine, Gastroenterology, Hepatology, and Oncology Krankenhaus Bad Cannstatt,
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationClinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2014.17.1.31 Pediatric Gastroenterology, Hepatology & Nutrition 2014 March 17(1):31-36 Original Article PGHN Clinical Course of Infliximab
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationReview article: induction therapy for patients with active ulcerative colitis
Alimentary Pharmacology & Therapeutics Review article: induction therapy for patients with active ulcerative colitis S. P. L. TRAVIS John Radcliffe Hospital and Linacre College, Oxford, UK Correspondence
More informationReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationThe variable risk of colorectal cancer in patients with inflammatory bowel disease.
The variable risk of colorectal cancer in patients with inflammatory bowel disease. Lindgren, Stefan Published in: European Journal of Internal Medicine DOI: 10.1016/j.ejim.2004.12.001 Published: 2005-01-01
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationPrevalence of Nonadherence With Maintenance Mesalamine in Quiescent Ulcerative Colitis
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 96, No. 10, 2001 2001 by Am. Coll. of Gastroenterology ISSN 0002-9270/01/$20.00 Published by Elsevier Science Inc. PII S0002-9270(01)03245-2 Prevalence of
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationLong-term outcome after infliximab for refractory ulcerative colitis
Journal of Crohn's and Colitis (2008) 2, 219 225 available at www.sciencedirect.com Long-term outcome after infliximab for refractory ulcerative colitis Marc Ferrante a, Séverine Vermeire a, Herma Fidder
More informationresults from a regional patient group from the county of Copenhagen
Gut, 1985, 26, 158-163 Long term prognosis in ulcerative colitis based on results from a regional patient group from the county of Copenhagen C HENDRIKSEN, S KREINER, AND V BINDER From the Medical-Gastroenterological
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More information5-aminosalicylic acid (5-ASA) is the mainstay of first-line therapy
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis Stephen B. Hanauer, MD 1 ; Gary R. Lichtenstein, MD 2 ; Michael A. Kamm, MD 3 ; William J. Sandborn, MD 4 ; Kirstin
More informationRandomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis
Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationUlcerative Colitis: State of the Art 2006
Ulcerative Colitis: State of the Art David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Improving Management of Ulcerative Colitis (UC) Better classification/diagnostic
More informationTopical therapy is underused in patients with ulcerative colitis
Journal of Crohn's and Colitis (2014) 8, 56 63 Available online at www.sciencedirect.com ScienceDirect Topical therapy is underused in patients with ulcerative colitis F. Seibold a, f,, N. Fournier b,
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationThe Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.
The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms
More informationCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL Azathioprine maintenance therapy in steroid-refractory Ulcerative Colitis responsive to i.v. Cyclosporine A: Is a therapeutic bridge with oral Cyclosporine A necessary? Miquel A.
More informationUlcerative Colitis: Experience at a Tertiary Care Center
Original Article Ulcerative Colitis: Experience at a Tertiary Care Center Nasir Khokhar From Division of gastroenterology, Department of Medicine, Shifa International Hospital and Shifa College of Medicine,
More informationWhat is ulcerative colitis?
What is ulcerative colitis? Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. Ulcers form where inflammation has killed the cells
More informationIBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationOVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON THE DEVELOPMENT OF NEW MEDICINAL PRODUCTS FOR THE TREATMENT OF ULCERATIVE COLITIS
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 21 February 2008 Doc. Ref. EMEA/468539/2007 OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON THE DEVELOPMENT
More information5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA
5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationEfficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
CLINICAL AND SYSTEMATIC S nature publishing group 601 Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis Alexander C. Ford, MBChB, MD, MRCP 1, 2, Je an - Pau l Ach
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationResponse to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients
Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients Tamás Molnár 1, Klaudia Farkas 1, Tibor Nyári 2, Zoltán Szepes 1, Ferenc Nagy 1,
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationInsurance problems among inflammatory bowel disease patients: results of a Dutch population based study
358 INFLAMMATORY BOWEL DISEASE Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study MGVMRussel, B M Ryan, P C Dagnelie, M de Rooij, J Sijbrandij, A Feleus,
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationConsecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis
Alimentary Pharmacology and Therapeutics Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis T. Yamamoto, T. Shimoyama
More informationIncidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:760 765 Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis DAVID N. MOSKOVITZ, GERT VAN
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationWHAT IS ULCERATIVE COLITIS?
235 60th Street, West New York, NJ 07093 T: (201) 854-4646 F: (201) 854-4647 810 Main Street, Hackensack, NJ 07601 T: (201) 488-0095 Ulcerative Colitis WHAT IS ULCERATIVE COLITIS? Ulcerative colitis is
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationThere is a well-established association between inflammatory
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1346 1350 Aminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative Colitis DAVID T. RUBIN, ANDELKA LOSAVIO, NICOLE YADRON,
More informationAs clinicians we would all agree that the goal for our
CURRENT CONTROVERSIES: PRO, CON, AND BALANCE Controversies in Mucosal Healing in Ulcerative Colitis Sunanda Kane, MD,* Frances Lu, MD, Asher Kornbluth, MD, Dahlia Awais, MD, and Peter D.R. Higgins, MD,
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationBridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists
ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 1-5 Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists Mohammad
More informationOp#mizing)Management)in)IBD:) Mucosal)Healing)
Op#mizing)Management)in)IBD:) Mucosal)Healing) Vipul&Jairath&MD&PhD& Associate&Professor&of&Medicine,&Epidemiology&and& Biosta=s=cs& Western&University&&& Division&of&Gastroenterology,&& London&Health&Sciences&Network&
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationCRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1
Colorectal Cancer and in IBD: A Case-Based Approach Fernando Velayos MD MPH Associate Director of Translational Research University of California, San Francisco Center for Crohn s s and Colitis CRC and
More informationCrohn's disease. Appendix J. Clinical Guideline < > 10 October Review of Cochrane ASA review
Crohn's disease Clinical Guideline < > Review of Cochrane ASA review 0 October 202 Commissioned by the National Institute for Health and Clinical Excellence Review of Cochrane 5-ASA review Contents Published
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationSpeaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 1-5 Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first real-life experience in
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationI nflammatory bowel diseases (IBD) are chronic intestinal
364 INFLAMMATORY BOWEL DISEASE Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn s disease F Costa, M G Mumolo, L Ceccarelli, M Bellini, M R Romano, C Sterpi,
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationUntil the late 1990s, treatment of Crohn s disease was primarily aimed at
CHALLENGES IN CROHN S DISEASE An Historical Overview of the Treatment of Crohn s Disease: Why Do We Need Biological Therapies? Paul J. Rutgeerts, MD, PhD, FRCP Faculty of Medicine, Gastroenterology Section,
More informationPreventing post-operative recurrence
Oxford Inflammatory Bowel Disease MasterClass Preventing post-operative recurrence Dr Oliver Brain Oxford Disclosures Presented at IEE, Oxford 2013 AbbVie sponsored meeting Talk Outline Risk factors for
More informationavailable at
Journal of Crohn's and Colitis (2009) 3, 32 37 available at www.sciencedirect.com An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from
More informationDeterminants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis
Research Article imedpub Journals http://www.imedpub.com/ Abstract Determinants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis Aims: The aim of our study was to identify the determinants
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationUnderstanding Inflammatory Bowel Diseases (IBD):
Understanding Inflammatory Bowel Diseases (IBD): What Every Patient Needs to Know William H Holderman, MD Digestive Health Specialists Tacoma, WA Today s Objectives Define IBD, its potential causes and
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationGary R. Lichtenstein, MD, FACG
Symposium B: Clinical Challenges in IBD A Case-based Approach refractory ibd Gary R. Lichtenstein, MD, FACG Key Take Home Points Establish the correct extent, type of IBD (UC versus CD) and establish disease
More informationThis program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda
This program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda Today s Presenter Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease
More informationT he treatment strategy for Crohn s disease (CD) is
237 INFLAMMATORY BOWEL DISEASE Impact of the increasing use of immunosuppressants in Crohn s disease on the need for intestinal surgery J Cosnes, I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, J-P
More informationAmerican Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis
1 American Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis Siddharth Singh, MD, MS 1 *; Joseph D. Feuerstein, MD 2 *; David G. Binion, MD 3 ; William
More informationFull title of guideline: Ulcerative colitis: the management of ulcerative colitis
Economic Plan This document identifies the priorities for economic analysis and the proposed methods for addressing these questions as described in section 7.1.3 of the Guidelines Manual (2009). 1 Guideline
More informationOutcomes of immunosuppressors and biologic drugs in inflammatory bowel diseases: a real life experience
Outcomes of immunosuppressors and biologic drugs in inflammatory bowel Treatments and therapeutic approaches in IBD are constantly evolving. The newly emerged biologic treatments are one such evolving
More informationUlcerative colitis (UC) is a chronic disease that is commonly
ORIGINAL ARTICLE Voting with Their Feet (VWF) Endpoint: A Meta-Analysis of an Alternative Endpoint in Clinical Trials, Using 5-ASA Induction Studies in Ulcerative Colitis Sujal C. Rangwalla, DO,* Akbar
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUntil recently, treatment of active ulcerative colitis
ORIGINAL ARTICLE Prognostic Significance of Endoscopic Remission in Patients with Active Ulcerative Colitis Treated with Oral and Topical Mesalazine: A Prospective, Multicenter Study Gianmichele Meucci,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC
ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation
More informationTreating Crohn s and Colitis in the ASC
Treating Crohn s and Colitis in the ASC Kimberly M Persley, MD Texas Digestive Disease consultants TASC Meeting Outline IBD 101 Diagnosis Treatment Burden of Disease Role of ASC Inflammatory Bowel Disease
More informationLiterature Review: CORE I & II: COlonic RElease Budesonide for the Induction of Remission for Mild- Moderate Ulcerative Colitis
VOLUME 13, ISSUE 1, YEAR 2014 Literature Review: CORE I & II: COlonic RElease Budesonide for the Induction of Remission for Mild- Moderate Ulcerative Colitis Peter R. McNally, DO, MACG, MSRF Center for
More informationWhich is the Safest Strategy to Treat Moderate to Severe IBD?
Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor
More informationDiagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases
Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Parakkal Deepak, M.B.B.S., M.S. Assistant Professor of Medicine Division of Gastroenterology John T. Milliken Department
More informationCrohn s disease is a chronic recurrent inflammation of the
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:1430 1438 Clinical Course in Crohn s Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study INGER CAMILLA SOLBERG,* MORTEN H. VATN, OLE
More informationLong-term follow-up of collagenous colitis after induction of clinical remission with budesonide
Aliment Pharmacol Ther 2005; 22: 1115 1119. doi: 10.1111/j.1365-2036.2005.02688.x Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide S. MIEHLKE*, A. MADISCH*,
More information